Small molecule neurolysin activators, potential multi-mechanism agents for ischemic stroke therapy

Shiva Hadi Esfahani; Thomas J Abbruscato; Paul C Trippier; Vardan T Karamyan

doi:10.1080/14728222.2022.2077190

Small molecule neurolysin activators, potential multi-mechanism agents for ischemic stroke therapy

Expert Opin Ther Targets. 2022 May;26(5):401-404. doi: 10.1080/14728222.2022.2077190. Epub 2022 May 19.

Authors

Shiva Hadi Esfahani¹, Thomas J Abbruscato^{1

2}, Paul C Trippier³, Vardan T Karamyan^{1

2}

Affiliations

¹ Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
² Center for Blood Brain Barrier Research, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
³ Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA.

PMID: 35543670
DOI: 10.1080/14728222.2022.2077190

No abstract available

Keywords: allosteric activator; allosteric enhancer; cerebroprotective therapy; drug-discovery; enzyme activator; multi-target; peptidase activator; stroke neuroprotection.

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Brain / metabolism
Humans
Ischemic Stroke*
Metalloendopeptidases / metabolism
Neuroprotective Agents*
Stroke* / drug therapy

Substances

Neuroprotective Agents
Metalloendopeptidases
neurolysin

Grants and funding

R01 NS106879/NS/NINDS NIH HHS/United States